At the cutting edge of regenerative medicine, Beike Biotechnology is dedicated to developing technologies and protocols for safe, effective translational research utilizing adult stem cells. We primarily focus on clinical translation with stem cells from three sources: allogeneic umbilical cord and cord blood and autologous bone marrow.
Our mission is to be the world leader in stem cell research and clinical translation, to make comprehensive cellular therapy accessible and cost-effective, and to improve each patient’s quality of life. Beike Biotechnology partners with over 250 doctors and scientists in the leading hospitals across China who are all specialists in delivering stem cell translation to treat serious illness including autoimmune, neurological and liver diseases.
Beike Biotechnology’s setting records in the stem cell translation
- First to collect the most comprehensive data of clinical safety study on human umbilical cord blood-derived mononuclear cell translation
- First blind patient recovered sight after receiving human umbilical cord blood-derived mononuclear cell translation
- First patient with systemic lupus erythematosus regained health after receiving human umbilical cord-derived mesenchymal stem cell translation
